RxforSafety.com - Actions to Help Reduce the Potential for Dispensing Errors Between TOPAMAX (topiramate) Tablets and TOPROL-XL (metroprolol succinate) extended-release tablets.

Healthcare Professional Resources

Recent Medication Errors

Home • Site Map • Contact Us

Recent News: Healthcare Professionals Alerted to Reported Medication Errors Between TOPAMAX®(topiramate) Tablets and TOPROL-XL^® (metroprolol succinate) extended-release tablets

For healthcare professionals, Ortho-McNeil Neurologics, Inc., offers these suggestions to help reduce the potential for future errors:

Be alert to the possibility of medication errors in patients taking TOPAMAX^® or TOPROL-XL^®.
Be aware the possibility of medication errors in patients presenting with unexpected signs or symptoms while on TOPAMAX or TOPROL-XL.
Confirm the brand and generic names and dosage prescribed on both written and oral prescriptions.
Write full and legible prescriptions for these products and communicate oral prescriptions clearly.
Counsel patients about the brand name, indication and proper use of each medication.

This site is published by Ortho-McNeil Neurologics, Inc., which is solely responsible for its contents.

This information is intended for the use of our customers, patients and healthcare professionals in the United States only. Ortho-McNeil Neurologics, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside of the United States.

TOPAMAX^®(topiramate) is a trademark of Ortho-McNeil Neurologics, Inc.

TOPROL^® and TOPROL-XL^® (metroprolol succinate) are registered trademarks of the AstraZeneca group of companies.

This page was last modified on: Tuesday, August 15, 2006 12:16 PM EST